Drugs / DWC202405
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06671392 | Feb 2025 → Feb 2026 | essential hypertension | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWC202405 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06671392 ↗ |
| Route | Oral | “5/20mg, 1 tablet, Oral, Once a day” NCT06671392 ↗ |